- Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
- Cellectis présente des données de recherche d’une nouvelle cellule CAR T universelle au congrès annuel de l’ASGCT
- Cellectis publie ses résultats financiers du premier trimestre 2022
- Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
- Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
- Monthly information on share capital and company voting rights
- Cellectis annonce ses résultats financiers pour le premier trimestre 2022
- Cellectis to Report First Quarter 2022 Financial Results
- Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
- Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
More ▼
Key statistics
As of last trade, Cellectis SA (ZVA:DUS) traded at 3.34, 22.99% above the 52 week low of 2.71 set on May 13, 2022.
52-week range
Markit short selling activity
Open | 3.35 |
---|---|
High | 3.46 |
Low | 3.32 |
Bid | 3.33 |
Offer | 3.37 |
Previous close | 3.28 |
Average volume | 0.00 |
---|---|
Shares outstanding | 45.48m |
Free float | 38.34m |
P/E (TTM) | -- |
Market cap | 134.83m EUR |
EPS (TTM) | -2.85 EUR |
Data delayed at least 15 minutes, as of May 18 2022 10:00 BST.
More ▼